Lillian L. Siu, MD

Director, Tumor Immunotherapy Program

Dr. Siu is a senior staff medical oncologist at Princess Margaret Cancer Centre since 1998, and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Cancer Centre. Dr. Siu is also the Director of the Tumor Immunotherapy Program at the Princess Margaret Cancer Centre.

Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award (2014-2019) sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution’s core vision to deliver precision cancer medicine.

Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010. She has held international leadership positions including the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10, and the Chairperson of the AACR Education Committee and Co-Chairperson of the Scientific Committee for the 2012 Annual Meeting. Dr. Siu is a scientific editor for Cancer Discovery and is on the editorial board for the Journal of Clinical Oncology and JAMA Oncology. She also serves on the Board of Directors for the ASCO for a four-year term (2012-2016). She also serves as a member of the Nomination Committee for the American Association for Cancer Research (2014-2016). She is a member of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH).